COVID-19 hospitalisations and all-cause mortality by risk group in Finland

被引:2
|
作者
Summanen, Milla [1 ]
Kosunen, Mikko [1 ]
Kainu, Ville [1 ]
Cansel, Anniina [2 ]
Niskanen, Severi [2 ]
Nurmi, Lalli [2 ]
Leskelae, Riikka-Leena [2 ]
Isomeri, Outi [2 ]
机构
[1] Pfizer Oy, Pfizer Biopharm Grp, Helsinki, Finland
[2] NHG Finland, Nord Healthcare Grp, Helsinki, Finland
来源
PLOS ONE | 2023年 / 18卷 / 05期
关键词
D O I
10.1371/journal.pone.0286142
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Ever since COVID-19 was announced as a global pandemic in March 2020, healthcare systems around the world have struggled with the burden of the disease. Vaccinations and other preventive measures have decreased this burden, but severe forms of COVID-19 leading to hospitalizations and even deaths still effect certain risk groups, such as the elderly and patients with multiple comorbidities. The objective of this retrospective observational study was to identify which risk groups are at the highest risk for a severe COVID-19 infection in Finland using national registry data ranging from January 2021 to June 2022. The data was analysed in three time periods, enabling comparisons in high-risk groups between epidemiological waves caused by different variants of SARS-CoV-2. The summary level data were stratified according to predefined groups based on two criteria: age (>= 18 years, 18-59 years, and >= 60 years) and risk group. The results include analysis of infection hospitalisation rate (IHR), case fatality rate (CFR) and average length of stay (LOS) in both primary and specialty care for each risk group and age group. Our results confirm that despite the decrease in COVID-19 hospitalisations and deaths observed during the study period, a significant proportion of patients are still hospitalised, and deaths occur especially in the 60+ population. Also, even though the average length of stay of hospitalised COVID-19 patients has decreased, it is still long compared to specialty care hospitalisations in general. Old age is a significant risk factor for severe COVID-19 in all patient groups and certain risk factors such as chronic kidney disease clearly increase the risk for severe COVID-19 outcomes. Early treatment should be considered with a low threshold for risk group patients and for elderly patients in order to avoid severe disease courses, and to ease the burden on hospitals where resources are currently very strained.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] IS TRANSAMINITIS AN INDEPENDENT RISK FACTOR FOR ALL-CAUSE MORTALITY IN COVID-19?
    Mughal, Mohsin
    Kaur, Ikwinder P.
    Kakadia, Mili
    Alhashemi, Reem
    Qudah, Hamzah A.
    Azad, Sarah
    Wang, Chang
    Mirza, Hasan M.
    Singh, Harjot
    Priya, Angi
    Eng, Margaret
    [J]. GASTROENTEROLOGY, 2021, 160 (06) : S851 - S851
  • [2] All-cause and COVID-19 mortality in Qatar during the COVID-19 pandemic
    AlNuaimi, Asma A.
    Chemaitelly, Hiam
    Semaan, Sandy
    AlMukdad, Sawsan
    Al-Kanaani, Zaina
    Kaleeckal, Anvar Hassan
    Latif, Ali Nizar
    Al-Romaihi, Hamad Eid
    Butt, Adeel A.
    Al-Thani, Mohamed H.
    Bertollini, Roberto
    AbdulMalik, Mariam
    Al-Khal, Abdullatif
    Abu-Raddad, Laith J.
    [J]. BMJ GLOBAL HEALTH, 2023, 8 (05):
  • [3] All-cause mortality during the COVID-19 pandemic in Peru
    Liu, Yanwen
    Zhao, Shi
    Yang, Lin
    Aliaga-Linares, Lissette
    He, Daihai
    [J]. IJID REGIONS, 2022, 5 : 177 - 179
  • [4] Impact of Metabolic Acidosis on All-Cause Mortality in Patients With COVID-19
    Kim, Yaerim
    Kwon, Soie
    Lee, Jeonghwan
    Paek, Jin Hyuk
    Park, Woo Yeong
    Jin, Kyubok
    Han, Seungyeup
    Kim, Dong Ki
    Lee, Jung Pyo
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 332 - 333
  • [5] Excess All-Cause Mortality During the COVID-19 Outbreak in Japan
    Yorifuji, Takashi
    Matsumoto, Naomi
    Takao, Soshi
    [J]. JOURNAL OF EPIDEMIOLOGY, 2021, 31 (01) : 90 - 92
  • [6] In COVID-19, tocilizumab reduces all-cause mortality at 28 d
    Fernando, Shannon M.
    Rochwerg, Bram
    [J]. ANNALS OF INTERNAL MEDICINE, 2021, 174 (06) : JC63 - JC63
  • [7] Predictors of All-Cause Mortality in Heart Transplant Recipients With COVID-19
    De Sirkar, Sovik
    Yu, Mingxi
    [J]. CIRCULATION, 2021, 144
  • [8] Anticoagulants and all-cause mortality among hospitalized COVID-19 patients
    Liang, Caihua
    Zhou, Li
    Doherty, Michael C.
    Gately, Robert V.
    Ogilvie, Rachel P.
    Chomistek, Andrea K.
    Wang, Florence
    Seeger, John D.
    Franklin, Jessica
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 78 - 78
  • [9] Platelet Activation is Associated With All-cause Mortality in Patients With Covid-19
    Barrett, Tessa J.
    Lee, Angela
    Xia, Yuhe
    Lin, Lawrence
    Black, Margaret
    Cotzia, Paolo
    Hochman, Judith S.
    Berger, Jeffrey S.
    [J]. CIRCULATION, 2020, 142
  • [10] Estimation of Excess All-Cause Mortality Due to COVID-19 in Thailand
    Wilasang, Chaiwat
    Modchang, Charin
    Lincharoen, Thanchanok
    Chadsuthi, Sudarat
    [J]. TROPICAL MEDICINE AND INFECTIOUS DISEASE, 2022, 7 (07)